Combination therapy for multiple myeloma and related blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination treatment for multiple myeloma and similar blood cancers. It aims to see if the combination works better than current options and may help people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma, plasma cell leukemia, or light-chain amyloidosis that is confirmed by a doctor.
- Your cancer must show a measurable sign in your blood or urine, like a specific protein level.
- You cannot have had severe side effects from similar cell-targeting treatments before.
- You must have completed certain prior treatments at least 4 weeks before the study starts, unless your doctor says otherwise.
- If you are taking a drug that contains pomalidomide, lenalidomide, or QL2109, you must not have had a bad reaction to it before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial is testing a new drug called QL2109 combined with Darzalex Faspro (daratumumab and hyaluronidase) for people with multiple myeloma that has returned or not responded to earlier treatments. The goal is to see if this combination can better control the cancer compared to standard options.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
Hear when a new Malignant Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.